Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orforglipron for obstructive sleep apnea in adults with overweight or obesity
jRCT2031240499Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Randomised, double-blind trial in obstructive sleep apnea hypopnea syndrome (OSAHS), obesity and Overweight comparing Orforglipron with Placebo (2 arms). Primary endpoint: Change from baseline in apnea-hypopnea index. Started Jan 2025; status: active, not recruiting.
02
Drugs
orforglipron
03
Conditions
obstructive sleep apnea hypopnea syndrome (OSAHS)obesityOverweight
Beyond the preview
Go deeper on jRCT2031240499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240499.